Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis
Background and Aims A number of studies have confirmed that antiviral therapy with nucleotide analogs (NAs) can improve the prognosis of hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) after curative therapy. However, what factors affected the prognosis of HBV‐HCC after removal of the...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology and hepatology 2015-06, Vol.30 (6), p.977-983 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 983 |
|---|---|
| container_issue | 6 |
| container_start_page | 977 |
| container_title | Journal of gastroenterology and hepatology |
| container_volume | 30 |
| creator | Zhou, Hua-ying Luo, Yue Chen, Wen-dong Gong, Guo-zhong |
| description | Background and Aims
A number of studies have confirmed that antiviral therapy with nucleotide analogs (NAs) can improve the prognosis of hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) after curative therapy. However, what factors affected the prognosis of HBV‐HCC after removal of the primary tumor and inhibition of HBV replication? A meta‐regression analysis was conducted to explore the prognostic factor for this subgroup of patients.
Methods
MEDLINE, EMBASE, Web of Science, and Cochrane library were searched from January 1995 to February 2014 for clinical trials evaluating the effect of NAs on the prognosis of HBV‐HCC after curative therapy. Data were extracted for host, viral, and intervention information. Single‐arm meta‐analysis was performed to assess overall survival (OS) rates and HCC recurrence. Meta‐regression analysis was carried out to explore risk factors for 1‐year OS rate and HCC recurrence for HBV‐HCC patients after curative therapy and antiviral therapy.
Results
Fourteen observational studies with 1284 patients met the inclusion criteria. Influential factors for prognosis of HCC were mainly baseline HBeAg positivity, cirrhotic stage, advanced Tumor‐Node‐Metastasis (TNM) stage, macrovascular invasion, and antiviral agent type. The 1‐year OS rate decreased by more than four times (coefficient −4.45, P |
| doi_str_mv | 10.1111/jgh.12917 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1676606981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1676606981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3637-6b236220f376ef03ca3073cd5f8f0980b530213997fd1614f9a53fd9bf616c0b3</originalsourceid><addsrcrecordid>eNp1kE1P2zAYgK2JaXRlh_0B5CM7pNhxYsfcaLW1TBVMYtN2sxznNRjyUewEyJk_PpcCN3ywJft5H8kPQl8pmdG4jm-urmc0lVR8QBOaZSShIuN7aEIKmieSUbmPPodwQwjJiMg_of0054XMaDFBTyvY6N71LuA5vnd-CLgZ-njTtbjRI97UcdPYdzVg1-LrLd0ZqOuh1h4b7Y1ruyYCYAbvoTVwgk9xGEMPTbSY-HDv4AHrtsIN9DrxcOUhhK1ft7oegwsH6KPVdYAvL-cU_fnx_fdilawvlmeL03ViGGci4WXKeJoSywQHS5jRjAhmqtwWlsiClDkjKWVSCltRTjMrdc5sJUvLKTekZFN0tPNufHc3QOhV48L2L7qFbgiKcsE54bKgEf22Q43vQvBg1ca7RvtRUaK2zVVsrp6bR_bwRTuUDVRv5GvkCBzvgAdXw_i-Sf1crl6VyW7CxY6PbxPa3youmMjV3_Olulxm83_r-S-1Zv8BFs2cCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1676606981</pqid></control><display><type>article</type><title>Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zhou, Hua-ying ; Luo, Yue ; Chen, Wen-dong ; Gong, Guo-zhong</creator><creatorcontrib>Zhou, Hua-ying ; Luo, Yue ; Chen, Wen-dong ; Gong, Guo-zhong</creatorcontrib><description>Background and Aims
A number of studies have confirmed that antiviral therapy with nucleotide analogs (NAs) can improve the prognosis of hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) after curative therapy. However, what factors affected the prognosis of HBV‐HCC after removal of the primary tumor and inhibition of HBV replication? A meta‐regression analysis was conducted to explore the prognostic factor for this subgroup of patients.
Methods
MEDLINE, EMBASE, Web of Science, and Cochrane library were searched from January 1995 to February 2014 for clinical trials evaluating the effect of NAs on the prognosis of HBV‐HCC after curative therapy. Data were extracted for host, viral, and intervention information. Single‐arm meta‐analysis was performed to assess overall survival (OS) rates and HCC recurrence. Meta‐regression analysis was carried out to explore risk factors for 1‐year OS rate and HCC recurrence for HBV‐HCC patients after curative therapy and antiviral therapy.
Results
Fourteen observational studies with 1284 patients met the inclusion criteria. Influential factors for prognosis of HCC were mainly baseline HBeAg positivity, cirrhotic stage, advanced Tumor‐Node‐Metastasis (TNM) stage, macrovascular invasion, and antiviral agent type. The 1‐year OS rate decreased by more than four times (coefficient −4.45, P < 0.001) and the 1‐year HCC recurrence increased by more than one time (coefficient 1.20, P = 0.003) when lamivudine was chosen for HCC after curative therapy, relative to entecavir for HCC.
Conclusions
HBV mutation may play a role in HCC recurrence. Entecavir or tenofovir, a high genetic barrier to resistance, should be recommended for HBV‐HCC patients.</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.12917</identifier><identifier>PMID: 25689418</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Antiviral Agents - therapeutic use ; Carcinoma, Hepatocellular - etiology ; Carcinoma, Hepatocellular - therapy ; Combined Modality Therapy ; Databases, Bibliographic ; Female ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; HBV ; Hepatitis B - complications ; Hepatitis B - drug therapy ; Hepatitis B - virology ; Hepatitis B virus - genetics ; hepatocellular carcinoma ; Humans ; Liver Neoplasms - etiology ; Liver Neoplasms - therapy ; Male ; Middle Aged ; Mutation - genetics ; Neoplasm Recurrence, Local ; nucleotide analogs ; Prognosis ; Regression Analysis ; Tenofovir - therapeutic use</subject><ispartof>Journal of gastroenterology and hepatology, 2015-06, Vol.30 (6), p.977-983</ispartof><rights>2015 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3637-6b236220f376ef03ca3073cd5f8f0980b530213997fd1614f9a53fd9bf616c0b3</citedby><cites>FETCH-LOGICAL-c3637-6b236220f376ef03ca3073cd5f8f0980b530213997fd1614f9a53fd9bf616c0b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgh.12917$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgh.12917$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25689418$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Hua-ying</creatorcontrib><creatorcontrib>Luo, Yue</creatorcontrib><creatorcontrib>Chen, Wen-dong</creatorcontrib><creatorcontrib>Gong, Guo-zhong</creatorcontrib><title>Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>Background and Aims
A number of studies have confirmed that antiviral therapy with nucleotide analogs (NAs) can improve the prognosis of hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) after curative therapy. However, what factors affected the prognosis of HBV‐HCC after removal of the primary tumor and inhibition of HBV replication? A meta‐regression analysis was conducted to explore the prognostic factor for this subgroup of patients.
Methods
MEDLINE, EMBASE, Web of Science, and Cochrane library were searched from January 1995 to February 2014 for clinical trials evaluating the effect of NAs on the prognosis of HBV‐HCC after curative therapy. Data were extracted for host, viral, and intervention information. Single‐arm meta‐analysis was performed to assess overall survival (OS) rates and HCC recurrence. Meta‐regression analysis was carried out to explore risk factors for 1‐year OS rate and HCC recurrence for HBV‐HCC patients after curative therapy and antiviral therapy.
Results
Fourteen observational studies with 1284 patients met the inclusion criteria. Influential factors for prognosis of HCC were mainly baseline HBeAg positivity, cirrhotic stage, advanced Tumor‐Node‐Metastasis (TNM) stage, macrovascular invasion, and antiviral agent type. The 1‐year OS rate decreased by more than four times (coefficient −4.45, P < 0.001) and the 1‐year HCC recurrence increased by more than one time (coefficient 1.20, P = 0.003) when lamivudine was chosen for HCC after curative therapy, relative to entecavir for HCC.
Conclusions
HBV mutation may play a role in HCC recurrence. Entecavir or tenofovir, a high genetic barrier to resistance, should be recommended for HBV‐HCC patients.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Carcinoma, Hepatocellular - etiology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Combined Modality Therapy</subject><subject>Databases, Bibliographic</subject><subject>Female</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>HBV</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B - drug therapy</subject><subject>Hepatitis B - virology</subject><subject>Hepatitis B virus - genetics</subject><subject>hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - etiology</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation - genetics</subject><subject>Neoplasm Recurrence, Local</subject><subject>nucleotide analogs</subject><subject>Prognosis</subject><subject>Regression Analysis</subject><subject>Tenofovir - therapeutic use</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kE1P2zAYgK2JaXRlh_0B5CM7pNhxYsfcaLW1TBVMYtN2sxznNRjyUewEyJk_PpcCN3ywJft5H8kPQl8pmdG4jm-urmc0lVR8QBOaZSShIuN7aEIKmieSUbmPPodwQwjJiMg_of0054XMaDFBTyvY6N71LuA5vnd-CLgZ-njTtbjRI97UcdPYdzVg1-LrLd0ZqOuh1h4b7Y1ruyYCYAbvoTVwgk9xGEMPTbSY-HDv4AHrtsIN9DrxcOUhhK1ft7oegwsH6KPVdYAvL-cU_fnx_fdilawvlmeL03ViGGci4WXKeJoSywQHS5jRjAhmqtwWlsiClDkjKWVSCltRTjMrdc5sJUvLKTekZFN0tPNufHc3QOhV48L2L7qFbgiKcsE54bKgEf22Q43vQvBg1ca7RvtRUaK2zVVsrp6bR_bwRTuUDVRv5GvkCBzvgAdXw_i-Sf1crl6VyW7CxY6PbxPa3youmMjV3_Olulxm83_r-S-1Zv8BFs2cCw</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Zhou, Hua-ying</creator><creator>Luo, Yue</creator><creator>Chen, Wen-dong</creator><creator>Gong, Guo-zhong</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201506</creationdate><title>Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis</title><author>Zhou, Hua-ying ; Luo, Yue ; Chen, Wen-dong ; Gong, Guo-zhong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3637-6b236220f376ef03ca3073cd5f8f0980b530213997fd1614f9a53fd9bf616c0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Carcinoma, Hepatocellular - etiology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Combined Modality Therapy</topic><topic>Databases, Bibliographic</topic><topic>Female</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>HBV</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B - drug therapy</topic><topic>Hepatitis B - virology</topic><topic>Hepatitis B virus - genetics</topic><topic>hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - etiology</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation - genetics</topic><topic>Neoplasm Recurrence, Local</topic><topic>nucleotide analogs</topic><topic>Prognosis</topic><topic>Regression Analysis</topic><topic>Tenofovir - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Hua-ying</creatorcontrib><creatorcontrib>Luo, Yue</creatorcontrib><creatorcontrib>Chen, Wen-dong</creatorcontrib><creatorcontrib>Gong, Guo-zhong</creatorcontrib><collection>Istex</collection><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Hua-ying</au><au>Luo, Yue</au><au>Chen, Wen-dong</au><au>Gong, Guo-zhong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2015-06</date><risdate>2015</risdate><volume>30</volume><issue>6</issue><spage>977</spage><epage>983</epage><pages>977-983</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background and Aims
A number of studies have confirmed that antiviral therapy with nucleotide analogs (NAs) can improve the prognosis of hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) after curative therapy. However, what factors affected the prognosis of HBV‐HCC after removal of the primary tumor and inhibition of HBV replication? A meta‐regression analysis was conducted to explore the prognostic factor for this subgroup of patients.
Methods
MEDLINE, EMBASE, Web of Science, and Cochrane library were searched from January 1995 to February 2014 for clinical trials evaluating the effect of NAs on the prognosis of HBV‐HCC after curative therapy. Data were extracted for host, viral, and intervention information. Single‐arm meta‐analysis was performed to assess overall survival (OS) rates and HCC recurrence. Meta‐regression analysis was carried out to explore risk factors for 1‐year OS rate and HCC recurrence for HBV‐HCC patients after curative therapy and antiviral therapy.
Results
Fourteen observational studies with 1284 patients met the inclusion criteria. Influential factors for prognosis of HCC were mainly baseline HBeAg positivity, cirrhotic stage, advanced Tumor‐Node‐Metastasis (TNM) stage, macrovascular invasion, and antiviral agent type. The 1‐year OS rate decreased by more than four times (coefficient −4.45, P < 0.001) and the 1‐year HCC recurrence increased by more than one time (coefficient 1.20, P = 0.003) when lamivudine was chosen for HCC after curative therapy, relative to entecavir for HCC.
Conclusions
HBV mutation may play a role in HCC recurrence. Entecavir or tenofovir, a high genetic barrier to resistance, should be recommended for HBV‐HCC patients.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>25689418</pmid><doi>10.1111/jgh.12917</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0815-9319 |
| ispartof | Journal of gastroenterology and hepatology, 2015-06, Vol.30 (6), p.977-983 |
| issn | 0815-9319 1440-1746 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1676606981 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antiviral Agents - therapeutic use Carcinoma, Hepatocellular - etiology Carcinoma, Hepatocellular - therapy Combined Modality Therapy Databases, Bibliographic Female Guanine - analogs & derivatives Guanine - therapeutic use HBV Hepatitis B - complications Hepatitis B - drug therapy Hepatitis B - virology Hepatitis B virus - genetics hepatocellular carcinoma Humans Liver Neoplasms - etiology Liver Neoplasms - therapy Male Middle Aged Mutation - genetics Neoplasm Recurrence, Local nucleotide analogs Prognosis Regression Analysis Tenofovir - therapeutic use |
| title | Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A41%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20B%20virus%20mutation%20may%20play%20a%20role%20in%20hepatocellular%20carcinoma%20recurrence:%20A%20systematic%20review%20and%20meta-regression%20analysis&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Zhou,%20Hua-ying&rft.date=2015-06&rft.volume=30&rft.issue=6&rft.spage=977&rft.epage=983&rft.pages=977-983&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.12917&rft_dat=%3Cproquest_cross%3E1676606981%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1676606981&rft_id=info:pmid/25689418&rfr_iscdi=true |